Nautilus Biotechnology, Inc. (NAUT)
NASDAQ: NAUT · Real-Time Price · USD
2.430
+0.070 (2.97%)
At close: Nov 18, 2026, 4:00 PM EST
2.400
-0.030 (-1.23%)
After-hours: Nov 18, 2026, 7:58 PM EST
Nautilus Biotechnology Employees
Nautilus Biotechnology had 128 employees as of September 30, 2026. The number of employees increased by 4 or 3.23% compared to the same quarter last year. That makes Nautilus Biotechnology the 29,912th largest employer in the world and 3,793rd in the United States.
Employees
128
Change (1Y)
4
Growth (1Y)
3.23%
Revenue / Employee
$3,313
Profits / Employee
-$457,680
Market Cap
309.51M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2026 | 128 | 4 | 3.23% |
| Jun 30, 2026 | 127 | -1 | -0.78% |
| Mar 31, 2026 | 127 | -7 | -5.22% |
| Dec 31, 2025 | 130 | -25 | -16.13% |
| Sep 30, 2025 | 124 | -37 | -22.98% |
| Jun 30, 2025 | 128 | -36 | -21.95% |
| Mar 31, 2025 | 134 | -29 | -17.79% |
| Dec 31, 2024 | 155 | -12 | -7.19% |
| Sep 30, 2024 | 161 | 1 | 0.63% |
| Jun 30, 2024 | 164 | 11 | 7.19% |
| Mar 31, 2024 | 163 | 10 | 6.54% |
| Dec 31, 2023 | 167 | 33 | 24.63% |
| Sep 30, 2023 | 160 | 33 | 25.98% |
| Jun 30, 2023 | 153 | 29 | 23.39% |
| Mar 31, 2023 | 153 | 34 | 28.57% |
| Dec 31, 2022 | 134 | 21 | 18.58% |
| Sep 30, 2022 | 127 | 30 | 30.93% |
| Jun 30, 2022 | 124 | 35 | 39.33% |
| Mar 31, 2022 | 119 | 30 | 33.71% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 754 |
| Kyverna Therapeutics | 172 |
| Inovio Pharmaceuticals | 112 |
| Scribe Therapeutics | 82 |
| Larimar Therapeutics | 71 |
| AgomAb Therapeutics NV | 62 |
| Altimmune | 57 |
| Vicore Pharma Holding AB | 50 |
NAUT News
- 21 days ago - Nautilus Biotechnology price target raised to $4 from $3.50 at Roth Capital - TheFly
- 22 days ago - Nautilus Biotechnology Earnings Call Transcript: Q3 2026 - Transcripts
- 22 days ago - Nautilus Biotechnology Earnings release: Q3 2026 - Filings
- 22 days ago - Nautilus Biotechnology Quarterly report: Q3 2026 - Filings
- 22 days ago - Nautilus Biotechnology reports Q3 EPS (12c) vs. (11c) last year - TheFly
- 22 days ago - Nautilus to Measure Proteoforms Driving Alzheimer's Disease and Cancer in ARPA-H-Funded SEEDS Consortium - GlobeNewsWire
- 22 days ago - Nautilus Biotechnology Reports Third Quarter 2026 Financial Results - GlobeNewsWire
- 4 weeks ago - Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026 - GlobeNewsWire